Feb 15, 2023 8:30am EST Artelo Biosciences to Present at MicroCap Rodeo’s Annual Winter Wonderland – Best Ideas Virtual Investor Conference on February 22, 2023
Feb 02, 2023 9:00am EST Artelo Biosciences Completes Enrollment of the Phase 1b Stage of its CAReS Clinical Trial Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
Jan 26, 2023 8:30am EST Artelo Biosciences to Present at Sequire Biotechnology Conference on February 2nd
Nov 08, 2022 8:00am EST Artelo Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
Sep 22, 2022 9:00am EDT Artelo Biosciences to Present at the 2022 Ladenburg Thalmann Healthcare Conference on September 29th
Sep 07, 2022 8:30am EDT Artelo Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Aug 16, 2022 9:00am EDT Artelo Biosciences Reports Positive Pre-Clinical Results with its Novel Inhibitor to Fatty Acid Binding Protein 5
Aug 09, 2022 8:10am EDT Artelo Biosciences Reports Second Quarter 2022 Financial Results and Provides Business Update
Jul 19, 2022 9:07am EDT Artelo Biosciences Completes Enrollment of the First Three Cohorts in its CAReS Study Evaluating ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
